Zuellig Pharma Launches Lilly's Innovative Obesity and Diabetes Medicine in Thailand
Mounjaro® (tirzepatide) will be available in the market from the end of May 2025
Mounjaro. Prescribing Information. Eli Lilly Asia, Inc. Division of Non-communicable Disease, Department of Disease Control, Ministry of Public Health) Yang, T., Qi, F., Guo, F. et al. An update on chronic complications of diabetes mellitus: from molecular mechanisms to therapeutic strategies with a focus on metabolic memory. Mol Med 30, 71 (2024). https://doi.org/10.1186/s10020-024-00824-9
BANGKOK, THAILAND - Media OutReach Newswire - 27 May 2025 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounjaro(tirzepatide), the innovative obesity and diabetes medicine developed by Eli Lilly and Company, will be launched in Thailand at the end of May 2025. Zuellig Pharma holds the marketing authorization for Mounjaro(tirzepatide) in Thailand, having been granted the distribution and promotion rights for the medicine by Eli Lilly and Company this year.Mounjaro(tirzepatide) is a once-weekly prescription-only medicine indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise; as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, in addition to other medicinal products for the treatment of diabetes; and as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m(obesity) or ≥27 kg/m2 to < 30 kg/m(overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).The availability of Mounjaro(tirzepatide) is a significant advancement in the treatment of both obesity and type 2 diabetes, offering a single medication that can address both conditions through an easy-to-use prefilled pen. MounjaroKwikPen(tirzepatide injection) is available in 2.5 mg, 5 mg, 7.5 mg and 10 mg, and gives healthcare providers the ability to personalize treatment plans better to meet individual patient needs.Obesity is a critical public health concern in Thailand that affects 48% of the total population.The Ministry of Public Health classifies obesity as a Non-Communicable Disease (NCD) due to its strong link to rising rates for chronic illnesses, particularly type 2 diabetes. In 2024, the Department of Disease Control reported that 1 in 10 Thai individuals – a total of 6.5 million people – suffer from type 2 diabetes, impacting their physical, mental, and social well-being.People with diabetes face significant challenges in managing their blood sugar and preventing complications such as cardiovascular disease, chronic kidney disease, diabetic retinopathy, and diabetic foot ulcers, which can lead to severe infections and potential amputation."Obesity and diabetes have gained prominence as significant health challenges in Thailand, and we are excited to accelerate the availability of Mounjaro(tirzepatide) to patients in the region. With our deep understanding of the local regulatory landscape, as well as our proven track record of delivering innovative healthcare solutions in unmet disease areas, we are well placed to enhance the availability of the medicine in the market. This represents a significant step forward in our commitment to making healthcare more accessible, particularly in the chronic metabolic disease market," said Rehan Saghir, Executive Vice President of Zuellig Pharma's Commercialization division.Hashtag: #ZuelligPharma #EliLillyandCompany #Diabetes #Obesity #Healthcare #Pharmaceuticals
The issuer is solely responsible for the content of this announcement.
About Zuellig Pharma
Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 17 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.
For more information, visit: https://www.zuelligpharma.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
27 minutes ago
- Malay Mail
Education Ministry to ramp up sex ed in schools by 2027 to curb harassment, online predators
KUALA LUMPUR, June 13 — The teaching time for the Reproductive and Social Health Education Guidelines (PEERS) module will be increased in the implementation of the 2027 School Curriculum. Education Minister Fadhlina Sidek said the module, which was launched in November last year, among other things, aims to increase reproductive health awareness among the community, especially students, teachers and parents. 'All MOE (Ministry of Education) educational institutions are requested to comply with the guidelines to address the issue of sexual harassment. Psychosocial support services also need to be further strengthened to provide support to students,' she said in a statement today. Fadhlina said MOE takes seriously media reports on the existence of paedophile pages on social media featuring school students and urged that such pages be reported immediately. 'The existence of social media pages that display pornographic and immoral content needs to be curbed,' she said. At the same time, she also urged parents to play a proactive role at home by educating and protecting children from the threat of sexual harassment. 'They are also responsible in ensuring that the dignity of children is preserved,' she said. — Bernama
Free Malaysia Today
17 hours ago
- Free Malaysia Today
Thai panel upholds suspension of doctors who helped Thaksin dodge jail
Thaksin Shinawatra remains a towering figure in Thai politics and is highly influential. (AFP pic) BANGKOK : Thailand's medical council on Thursday upheld its suspension of two doctors who enabled influential politician Thaksin Shinawatra to spend his prison sentence in hospital, a day ahead of the start of a Supreme Court case that could see him jailed. Thaksin, the driving force behind the current government, returned from 15 years of self-exile in 2023 to serve a prison term for abuse of power and conflicts of interest, but was sent to hospital after only a few hours in jail complaining of chest problems. The polarising billionaire, whose daughter Paetongtarn Shinawatra is prime minister, stayed in a VIP wing of the hospital for six months until his release on parole without a single night in jail, prompting public outrage and deep scepticism about the extent of his ailments. 'More than two-thirds of the council voted to uphold the punishments,' medical council of Thailand vice president, Prasit Watanapa, told reporters. 'Members made the decision based on medical principles, evidence and reason.' The suspensions could impact a case at the Supreme Court that begins on Friday in which the legality of Thaksin's hospital stay has been challenged, with the possibility the tycoon could be made to serve that time again, in prison. Thaksin, 75, remains a towering figure in Thai politics and though he holds no formal government role, he is highly influential. His lawyer declined to comment on Thursday on the council's decision. The revival of the controversy over Thaksin's hospital stay comes at a challenging time for Paetongtarn's government, which is seeing its popularity dwindle amid a prolonged struggle to spur economic growth and domestic pressure to take a tougher stance on an ongoing border dispute with Cambodia. Thaksin's sentence was originally eight years, but it was commuted to a year by the king and he became eligible for parole after six months. The medical council's vote overrides a veto of its earlier decision by health minister Somsak Thapsutin, a Thaksin ally. The council had yet to confirm the duration of the suspension of the two doctors, who it found had issued documents that contained false medical information. They had denied wrongdoing and stood by their medical assessments. Another doctor with the corrections department received a warning for failing to meet medical standards in a referral notice for Thaksin.
Free Malaysia Today
a day ago
- Free Malaysia Today
Traces of insecticides detected in rainwater in Japan
Japanese researchers say certain insecticides are also present in rainwater. (Envato Elements pic) PARIS : Pesticides don't just contaminate the air humans breathe or the food they eat. According to recent research conducted in Japan, certain insecticides are also present in rainwater. Scientists at Japan's University of Tokyo recently made a worrying discovery. Residues of several insecticides belonging to the well-known neonicotinoid family have been detected in rainwater. In Japan, neonicotinoids were introduced on a large scale in the 1990s, particularly in rice fields and pine forests. To reach this conclusion, the scientists collected and analysed rainwater samples from the cities of Tsukuba and Kashiwa, both located northeast of Tokyo. Their analyses were carried out between April 2023 and September 2024. They reveal that 91% of samples contained several insecticides from the neonicotinoid family. The highest total concentration was detected in August 2024, the study authors note. Acetamiprid is the predominant insecticide, having been identified in 82% of samples, followed by thiacloprid (73%) and dinotefuran (45%), two other insecticides from the neonicotinoid family. 'This research is the first report on neonicotinoid presence in precipitation, suggesting that neonicotinoids, as low volatile matter, can still be dispersed to the environment via precipitation,' warned the researchers, whose work is published in the journal Environmental Monitoring and Contaminants Research. Potential effects on human health In 2019, another study (also conducted by researchers at the University of Tokyo), published in the journal Science, explained in detail how the large-scale use of neonicotinoids contributed to the destruction of several species of fish, crustaceans, and zooplankton in Lake Shinji (southwestern Japan). Starting in 1993, several rice farmers began spraying imidacloprid on their fields. According to the study, the introduction of this insecticide in areas geographically close to the lake coincided with an 83% decrease in the average zooplankton biomass. While the harmful effects of neonicotinoids on insects (particularly bees) and several other animal species are increasingly well documented, doubts remain about their impact on human health. Given that neonicotinoids target the nervous system, scientists fear (among other things) that exposure to these substances may be linked to neurological disorders. However, these risks remain uncertain at present due to a lack of large-scale studies on the subject.
